Cardiovascular Disease and Dyslipidemia: Beyond LDL

被引:59
作者
Poess, Janine [1 ]
Custodis, Florian [1 ]
Werner, Christian [1 ]
Weingaertner, Oliver [1 ]
Boehm, Michael [1 ]
Laufs, Ulrich [1 ]
机构
[1] Univ Saarland, Innere Med Klin 3, Homburg, Germany
关键词
Dyslipidemia; LDL; HDL; Triglycerides; CETP; ESTER TRANSFER PROTEIN; CORONARY-HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; TYPE-2; DIABETES-MELLITUS; EXTENDED-RELEASE NIACIN; DOUBLE-BLIND; RISK-FACTORS; NONFASTING TRIGLYCERIDES; CAROTID ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION;
D O I
10.2174/138161211795428858
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Low-density lipoproteins (LDL) are atherogenic and represent a strong cardiovascular risk factor. Therefore, LDL-cholesterol (LDL-C) remains the primary target in lipid lowering therapy. However, since many cardiovascular events occur despite an optimal LDL-C, it is necessary to focus on the remaining cardiovascular risk. Treatment of low high-density lipoprotein-cholesterol (HDL-C) and high triglycerides (TG) are options to achieve cardiovascular risk reduction beyond LDL. HDL mediates reverse cholesterol transport and exerts several other athero-protective effects. Epidemiologic evidence has shown that low HDL-cholesterol (HDL-C) is a strong and independent cardiovascular risk marker. However, since the anti-atherogenic effects of HDL particles depend on their functionality rather than on their cholesterol content, an increase in HDL-C concentration does not always have to result in a clinical benefit. Besides established strategies to increase HDL-C, e. g. with fibrates and nicotinic acid, CETP (Cholesteryl ester transfer protein)-inhibition is a promising new therapeutic option. The failure of torcetrapib, the first CETP-inhibitor, seems to be attributed to "off-target" effects. Treatment with the newer CETP-inhibitors dalcetrapib and anacetrapib has been shown to be efficacious and safe - but their usefulness in clinical practice remains to be determined in ongoing clinical endpoint trials. TG concentrations have been shown to correlate with cardiovascular risk. However, interpretation of plasma TG concentrations remains difficult due to considerable intra-individual variability of plasma concentrations. Post-prandial triglyceride concentrations may be better predictors of cardiovascular risk than fasting TG. In patients with hypertriglyceridemia, achievement of the LDL-C goal remains the primary lipid target. The basis of therapy in patients with hypertriglyceridemia are life style modifications. In addition, non-HDL-C should be addressed. For selected patients, treatment with fibrates, nicotinic acid or omega-3 fatty acids are available to lower TG concentrations. In summary, the focus of lipid therapy is the reduction of cardiovascular risk rather than the modification of lipoprotein sub-fractions. Ongoing research points towards a shift of the focus from the HDL-C concentrations to parameters of HDL function and from fasting TG to TG kinetics.
引用
收藏
页码:861 / 870
页数:10
相关论文
共 86 条
[1]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[2]   Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men [J].
Assmann, G ;
Schulte, H ;
vonEckardstein, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (14) :1179-1184
[3]   THE PROSPECTIVE CARDIOVASCULAR MUNSTER (PROCAM) STUDY - PREVALENCE OF HYPERLIPIDEMIA IN PERSONS WITH HYPERTENSION AND OR DIABETES-MELLITUS AND THE RELATIONSHIP TO CORONARY HEART-DISEASE [J].
ASSMANN, G ;
SCHULTE, H .
AMERICAN HEART JOURNAL, 1988, 116 (06) :1713-1724
[4]   Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study [J].
Austin, MA ;
McKnight, B ;
Edwards, KL ;
Bradley, CM ;
McNeely, MJ ;
Psaty, BM ;
Brunzell, JD ;
Motulsky, AC .
CIRCULATION, 2000, 101 (24) :2777-2782
[5]   PLASMA TRIGLYCERIDE AND CORONARY HEART-DISEASE [J].
AUSTIN, MA .
ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (01) :2-14
[6]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[7]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[8]   Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women [J].
Bansal, Sandeep ;
Buring, Julie E. ;
Rifai, Nader ;
Mora, Samia ;
Sacks, Frank M. ;
Ridker, Paul M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (03) :309-316
[9]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[10]   Antiinflammatory properties of HDL [J].
Barter, PJ ;
Nicholls, S ;
Rye, KA ;
Anantharamaiah, GM ;
Navab, M ;
Fogelman, AM .
CIRCULATION RESEARCH, 2004, 95 (08) :764-772